Table 2.

Corticosteroid drug use at baseline and follow-up

 Any CS use (n)Systemic CS use (n)Local CS use (n)
No CS use at T1 or T261 937 (76%)
CS use at either T1 or T219 424235118 292
 Discontinuation at follow-up5540 (7%)3725448
 New CS use8867 (11%)18128130
 CS use at both T1 and T25017 (6%)1674714
 Any CS use (n)Systemic CS use (n)Local CS use (n)
No CS use at T1 or T261 937 (76%)
CS use at either T1 or T219 424235118 292
 Discontinuation at follow-up5540 (7%)3725448
 New CS use8867 (11%)18128130
 CS use at both T1 and T25017 (6%)1674714

“Any CS use”: either systemic CS use or local CS use.

“Discontinuation at follow-up”: CS use reported at T1, but not at T2.

“New CS use”: CS use only reported at T2, not at T1.

Abbreviations: CS, corticosteroid; T1, baseline assessment; T2, second assessment.

Table 2.

Corticosteroid drug use at baseline and follow-up

 Any CS use (n)Systemic CS use (n)Local CS use (n)
No CS use at T1 or T261 937 (76%)
CS use at either T1 or T219 424235118 292
 Discontinuation at follow-up5540 (7%)3725448
 New CS use8867 (11%)18128130
 CS use at both T1 and T25017 (6%)1674714
 Any CS use (n)Systemic CS use (n)Local CS use (n)
No CS use at T1 or T261 937 (76%)
CS use at either T1 or T219 424235118 292
 Discontinuation at follow-up5540 (7%)3725448
 New CS use8867 (11%)18128130
 CS use at both T1 and T25017 (6%)1674714

“Any CS use”: either systemic CS use or local CS use.

“Discontinuation at follow-up”: CS use reported at T1, but not at T2.

“New CS use”: CS use only reported at T2, not at T1.

Abbreviations: CS, corticosteroid; T1, baseline assessment; T2, second assessment.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close